Management

1. Assessment of severity of myopathy.

2. It had been suggested that all patients with central core disease should be considered to be at risk for malignant hyperthermia unless in vitro contracture tests show that the particular patient is free from the trait (Shuaib et al 1987). Not all patients with central core disease are susceptible to MH, and the disease is genetically heterogeneous (Curran et al 1999).The importance of all individuals with CCD being screened, regardless of the MH status of their relatives, has therefore been stressed (Halsall et al 1996, Curran et al 1999). If testing is not undertaken, individuals and their families will have to be treated as for MH, with all its implications.

3. Examination for mitral valve prolapse.

4. Avoidance of suxamethonium.

Bibliography

Allen GC, Brubaker CL 1998 Human malignant hyperthermia associated with desflurane anesthesia. Anesthesia & Analgesia 86:1328—31. Calore EE, Cavaliere MJ, Perez NM et al 1994

Hyperthermic reaction to haloperidol with rigidity, associated to central core disease. Acta Neurologica 16:157-61.

Curran JL, Hall WJ, Halsall PJ et al 1999 Segregration of malignant hyperthermia, central core disease and chromosome 19 markers. British Journal of Anaesthesia 83:217-22. Frank JP, HaratiY, Butler IJ et al 1980 Central core disease and malignant hyperthermia syndrome. Annals of Neurology 7:11-17. Gamble JG,Rinsky LA, Lee JH 1988 Orthopedic aspects of central core disease. Journal of Bone & Joint Surgery 70A: 1061-6. Garrido S, Fraga M, Martin MJ et al 1999 Malignant hyperthermia during desflurane-succinylcholine anesthesia for orthopedic surgery. Anesthesiology 90:1208-9.

Haan EA, Freemantle CJ, Mccure JA et al 1990 Assignment of the gene for central core disease to chromosome 19. Human Genetics 86: 187-90. Halsall PJ, Bridges LR, Ellis FR et al 1996 Should patients with central core disease be screened for malignant hyperthermia? Journal of Neurology, Neurosurgery & Psychiatry 61:119-21. Harriman DGF 1986 The definition of normal muscle and of malignant hyperthermia and the association of myopathies with the malignant hyperthermia trait. Muscle & Nerve 9 (suppl 1) 222.

Loke J, MacLennan DH 1998 Malignant hyperthermia and central core disease: disorders of Ca2+ release channels.American Journal of Medicine 104: 470-86.

Otsuka H, Komura Y, Mayumi T et al 1991 Malignant hyperthermia during sevoflurane anesthesia in a 1

child with central core disease.Anesthesiology 75: s

699-701. a

Prescott RJ, Roberts SP, Williams G 1992 Malignant i hyperpyrexia: a rare cause of postoperative death. i

Journal of Clinical Pathology 45: 361-3. o

Shuaib A, Paasuke RT, Brownell KW 1987 Central d core disease. Clinical features in 13 patients. c

Medicine 66: 389-96. ien

Was this article helpful?

0 0

Post a comment